Halozyme TherapeuticsHALO +3.19%92 Altman Z-Score is 3.78 as of Jun. 28, 2026, which is 16% below its 10-year median of 4.48. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.32 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 933 Biotechnology companies, Halozyme Therapeutics ranks better than 57.45% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.78 is strong.
Halozyme Therapeutics has a Altman Z-Score of 3.78, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Halozyme Therapeutics's Altman Z-Score or its related term are showing as below:
HALO'
s Altman Z-Score Range Over the Past 10 Years
Min: -0.19 Med: 4.48 Max: 9.81
Current: 3.78
During the past 13 years, Halozyme Therapeutics's highest Altman Z-Score was 9.81. The lowest was -0.19. And the median was 4.48.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Halozyme Therapeutics Altman Z-Score Related Terms
Halozyme Therapeutics Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HALO vs IBRX, TECH, CORT: Altman Z-Score Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Halozyme Therapeutics (HALO) has a Altman Z-Score of 3.78 as of Jun. 28, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Halozyme Therapeutics and its competitors. This is 16% below median its historical median of 4.48. According to the industry distribution chart, Halozyme Therapeutics ranks #397 out of 933 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Halozyme Therapeutics' Altman Z-Score too high?
Halozyme Therapeutics' current Altman Z-Score of 3.78 is 16% below median its 10-year median of 4.48. The Biotechnology industry median Altman Z-Score is 2.55. Halozyme Therapeutics' value of 3.78 is 48.2% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #397 out of 933 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Altman Z-Score compare to IBRX and TECH?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #397 out of 933 companies for Altman Z-Score. This puts Halozyme Therapeutics in the upper half of its industry. The industry median Altman Z-Score is 2.55. Halozyme Therapeutics' value of 3.78 is 48.2% above this benchmark. While the company's 10-year median is 4.48 vs. the industry median of 2.55, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.55, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Altman Z-Score of 3.78 is 48.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Altman Z-Score is 3.78, which is 16% below median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.32, compared to a current price of $74.96 — trading 17% below its estimated fair value. The current Altman Z-Score is 3.78, which is 16% below median its 10-year median of 4.48 and 48.2% above the Biotechnology industry median of 2.55. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Altman Z-Score is 3.78 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $74.96 is trading 17% below its estimated GF Value™ of $90.32.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Altman Z-Score: 3.78 (16% below median its 10-year median of 4.48)
GF Value™: $90.32 vs. price of $74.96 (17% below fair value)
Industry Position: 48.2% above the Biotechnology median (#397 of 933)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
